1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents
نویسندگان
چکیده
منابع مشابه
Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents
Second-generation metallic drug-eluting stents (DES) have been widely recommended for percutaneous coronary intervention. One of the main drawbacks of these devices is the risk of late adverse events (ie, beyond 1 year), particularly repeat revascularization, which are partly related to the persistence of the metallic stents in the coronary artery wall. In this context, the bioresorbable vascul...
متن کاملComparison of Everolimus- and Biolimus-Eluting Coronary Stents With€Everolimus-Eluting Bioresorbable Vascular Scaffolds
Fro ini Du an res da Bio (CR Lis Yo Ma BACKGROUND The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES). OBJECTIVES This study sought to compare the performance of a BVS with that of everolimus-eluting stents (EES) and biolimus-elutin...
متن کاملIntraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
BACKGROUND The performance of everolimus-eluting bioresorbable vascular scaffold (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percutaneous coronary intervention (PCI) remains poorly studied. This report investigates the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up angiography. METHODS AND RESULTS ...
متن کامل1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
OBJECTIVES The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. BACKGROUND Randomized studies of the ABSORB BRS have been performed in selected patient and les...
متن کاملComparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) Running title: Kimura et al.; Everolimus-eluting versus Sirolimus-eluting stents
Takeshi Kimura, MD; Takeshi Morimoto, MD; Masahiro Natsuaki, MD; Hiroki Shiomi, MD; Keiichi Igarashi, MD; Kazushige Kadota, MD; Kengo Tanabe, MD; Yoshihiro Morino, MD; Takashi Akasaka, MD; Yoshiki Takatsu, MD; Hideo Nishikawa, MD; Yoshito Yamamoto, MD; Yoshihisa Nakagawa, MD; Yasuhiko Hayashi, MD; Masashi Iwabuchi, MD; Hisashi Umeda, MD; Kazuya Kawai, MD; Hisayuki Okada, MD; Kazuo Kimura, MD; C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Cardiovascular Interventions
سال: 2016
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2015.10.042